Company profile for HaemaLogiX

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships. HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we...
The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships. HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development efforts to treat multiple myeloma.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
Suite 204, 80 William Street Woolloomooloo NSW 2011
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/haemalogix-welcomes-former-australian-federal-minister-for-health-professor-the-hon-greg-hunt-to-the-company-board-as-non-executive-director-302149935.html

PR NEWSWIRE
20 May 2024

https://www.prnewswire.com/news-releases/haemalogix-announces-appointment-of-damian-clarke-bruce-as-managing-director-and-ceo-301986694.html

PR NEWSWIRE
13 Nov 2023

https://www.contractpharma.com/contents/view_breaking-news/2023-07-25/haemalogix-peter-maccallum-cancer-centre-partner-on-myeloma-car-t-trial/?widget=listSection

CONTRACT PHARMA
25 Jul 2023

https://www.prnewswire.com/news-releases/haemalogix-announces-positive-final-results-from-kappamab-combination-phase-iib-myeloma-trial-301866728.html

PR NEWSWIRE
29 Jun 2023
HaemaLogix's myeloma drug boosts responses in Revlimid combo
HaemaLogix's myeloma drug boosts responses in Revlimid combo

29 Jun 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/australian-biotechs-myeloma-antibody-shows-benefits-phase-2-when-added-revlimib

James Waldron FIERCE BIOTECH
29 Jun 2023

https://www.prnewswire.com/news-releases/haemalogix-to-present-final-data-from-anti-kma-car-t-preclinical-studies-at-aacr-301782747.html

PR NEWSWIRE
27 Mar 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty